GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BiomX Inc (AMEX:PHGE) » Definitions » Change In Other Working Capital

BiomX (PHGE) Change In Other Working Capital : $-0.29 Mil (TTM As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is BiomX Change In Other Working Capital?

BiomX's Change In Other Working Capital for the quarter that ended in Sep. 2024 was $-0.51 Mil. It means BiomX's Other Working Capital declined by $0.51 Mil from Jun. 2024 to Sep. 2024 .

BiomX's Change In Other Working Capital for the fiscal year that ended in Dec. 2023 was $0.73 Mil. It means BiomX's Other Working Capital increased by $0.73 Mil from Dec. 2022 to Dec. 2023 .


BiomX Change In Other Working Capital Historical Data

The historical data trend for BiomX's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BiomX Change In Other Working Capital Chart

BiomX Annual Data
Trend Jun18 Jun19 Dec20 Dec21 Dec22 Dec23
Change In Other Working Capital
Get a 7-Day Free Trial - -0.07 2.01 0.85 0.73

BiomX Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Change In Other Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.60 0.11 -0.82 0.93 -0.51

BiomX Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BiomX Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of BiomX's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


BiomX Business Description

Industry
Traded in Other Exchanges
N/A
Address
22 Einstein Street, Floor 4, Ness Ziona, ISR, 7414003
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.
Executives
Orbimed Israel Biofund Gp Limited Partnership director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629
Assaf Oron officer: Chief Business Officer C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Eddie Williams director 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Michael E. Dambach director 22 EINSTEIN STREET, FLOOR 4, NESS ZIONA L3 7414003
Jason M. Marks director C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER NJ 08807
Carl L Gordon 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Chidozie Ugwumba 10 percent owner 158 FILMORE STREET, DENVER CO 80206
Thomas Layton Walton 10 percent owner P.O. BOX 1860, BENTONVILLE AR 72712
Paul J Sekhri director C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588
Lynne Marie Sullivan director C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Marina Wolfson officer: Principal Financial Officer C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Jonathan Eitan Solomon director, officer: Chief Executive Officer C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Alan Charles Moses director C/O 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Russell Greig director C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Gbolahan Amusa director 17 STATE STREET 21 FLOOR, NEW YORK NY 10004

BiomX Headlines

From GuruFocus

Q3 2022 Biomx Inc Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q2 2024 Biomx Inc Earnings Call Transcript

By GuruFocus News 10-09-2024

Q1 2023 Biomx Inc Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q2 2020 Biomx Inc Earnings Call Transcript

By GuruFocus Research 02-14-2024

Biomx Inc (PHGE) CEO Jonathan Eitan Solomon Bought $100,000 of Shares

By GuruFocus Research GuruFocus Editor 07-30-2021

Q4 2021 Biomx Inc Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q3 2021 Biomx Inc Earnings Call Transcript

By GuruFocus Research 02-14-2024

BiomX Inc. Announces $15 Million Registered Direct Offering

By Marketwired Marketwired 07-26-2021